The Pulse Report 2026
The Pulse: Global R&D Insights in Pharmaceuticals
Uncertainty is shaping every major decision in drug development. See what 150 global biotech and pharma leaders say about navigating cost, complexity, regulation, AI, and partnerships in 2026.
✓
R&D priorities in an uncertain market
✓
AI’s impact on development performance
✓
Strategies gaining traction
✓
Managing the speed–cost–complexity tradeoff
Sneak peek
Three signals defining drug development in 2026
Industry confidence in trajectories is wavering
While most believe the industry is moving forward, a significant minority of 2 in 5 sponsors question its trajectory. Heightened regulatory volatility and macroeconomic pressure fuel hesitation.
Protocol complexity has reached a tipping point
Nearly three-quarters of sponsors acknowledge that trial designs are more complex than necessary, yet many still rely on that complexity to meet objectives. The tradeoffs are becoming harder to manage.
Innovation and progress are not moving fast enough
Despite advances in science and technology, more than half of leaders believe progress is lagging expectations. Competitive pressure is rising as the pace of execution struggles to keep up.
What does this mean for your organization in 2026?
Download the full Pulse report to explore the data behind these shifts and see how drug development leaders are positioning for success.
Recommended for you
